• 1
    Yunus M, Masi AT, Calabro JJ, Miller KA, Feigenbaum SL: Primary fibromyalgia (fibrositis): clinical study of 50 patients with matched normal controls. Semin Arthritis Rheum 11: 151171, 1981
  • 2
    Wolfe F, Hawley DJ, Cathey MA, Caro XJ, Russell IJ: Fibrositis symptom frequency and criteria for diagnosis: an evaluation of 291 rheumatic disease patients and 58 normal individuals. J Rheumatol 12: 11591163, 1985
  • 3
    Campbell SM, Clark S, Tindall EA, Forehand ME, Bennett RM: Clinical characteristics of fibrositis. I. A “blinded,” controlled study of symptoms and tender points. Arthritis Rheum 26: 817824, 1983
  • 4
    Alarcón-Segovia D, Ramos-Niembro F, González-Amaro RF: One thousand private rheumatology patients in Mexico City (letter). Arthritis Rheum 26: 688689, 1983
  • 5
    Wolfe F: The epidemiology of fibromyalgia. J Musculoskel Pain 1: 137147, 1993
  • 6
    Russell IJ, Fletcher EM, Tsui J, Michalek JE: Comparisons of rheumatoid arthritis and fibrositis/fibromyalgia syndrome using functional and psychological outcome measures (abstract). Arthritis Rheum 32 (suppl 4): S70, 1989
  • 7
    Cathey MA, Wolfe F, Kleinheksel SM: Functional ability and work status in patients with fibromyalgia. Arthritis Care Res 1: 8598, 1988
  • 8
    Hamm C, Derman S, Russell IJ: Sleep parameters in fibrositis/fibromyalgia syndrome (abstract). Arthritis Rheum 32 (suppl 4): S70, 1989
  • 9
    Baum J: Joint pain: it isn't always arthritis. Postgrad Med 85: 311316, 1989
  • 10
    Yunus MB, Kalyan-Raman UP, Masi AT, Aldag JC: Electron microscopic studies of muscle biopsy in primary fibromyalgia syndrome: a controlled and blinded study. J Rheumatol 16: 97101, 1989
  • 11
    Kellgren JH: Observations on referred pain arising from muscle. Clin Sci 3: 175190, 1939
  • 12
    Riddoch G: The clinical features of central pain. Lancet 1: 1093, 1150, 1205, 1938
  • 13
    Arroyo JF, Cohen ML: Abnormal responses to electrocutaneous stimulation in fibromyalgia. J Rheumatol 20: 19251931, 1993
  • 14
    Reynolds WJ, Chiu B, Inman RD: Plasma substance P levels in fibrositis. J Rheumatol 15: 18021803, 1988
  • 15
    Vaeroy H, Helle R, Forre O, Kass E, Terenius L: Elevated CSF levels of substance P and high incidence of Raynaud's phenomenon in patients with fibromyalgia: new features for diagnosis. Pain 32: 2126, 1988
  • 16
    Vaeroy H, Helle R, Forre O, Kass E, Terenius L: Cerebrospinal fluid levels of beta-endorphin in patients with fibromyalgia (fibrositis syndrome). J Rheumatol 15: 18041806, 1988
  • 17
    Vaeroy H, Nyberg F, Terenius L: No evidence for endorphin deficiency in fibromyalgia following investigation of cerebrospinal fluid (CSF) dynorphin A and Met-enkephalin-Arg6-Phe7. Pain 46: 139143, 1991
  • 18
    Murphy RM, Zemlan FP: Differential effects of substance P on serotonin-modulated spinal nociceptive reflexes. Psychopharmacology (Berlin) 93: 118121, 1987
  • 19
    Harvey JA, Schlosberg AJ, Yunger LM: Behavioral correlates of serotonin depletion. Fed Proc 34: 17961801, 1975
  • 20
    Moldofsky H, Warsh JJ: Plasma tryptophan and musculoskeletal pain in nonarticular rheumatism (“fibrositis syndrome”). Pain 5: 6571, 1978
  • 21
    Russell IJ, Vipraio GA, Lopez YG: Serum serotonin in fibromyalgia syndrome, rheumatoid arthritis, osteoarthritis and healthy normal controls (abstract). Arthritis Rheum 36 (suppl 9): S222, 1993
  • 22
    Russell IJ, Michalek JE, Vipraio GA, Fletcher EM, Javors MA, Bowden CA: Platelet 3H-imipramine uptake receptor density and serum serotonin levels in patients with fibromyalgia/fibrositis syndrome. J Rheumatol 19: 104109, 1992
  • 23
    Hrycaj P, Stratz T, Muller W: Platelet 3H-imipramine uptake receptor density and serum serotonin in patients with fibromyalgia/fibrositis syndrome. J Rheumatol 20: 19861987, 1993
  • 24
    Wolfe F, Smythe HA, Yunus MB, Bennett RM, Bombardier C, Goldenberg DL, Tugwell P, Campbell SM, Abeles M, Clark P, Fam AG, Farber SJ, Fiechtner JJ, Franklin CM, Gatter RA, Hamaty D, Lessard J, Lichtbroun AS, Masi AT, McCain GA, Reynolds WJ, Romano TJ, Russell IJ, Sheon RP: The American College of Rheumatology 1990 criteria for the classification of fibromyalgia: report of the multicenter criteria committee. Arthritis Rheum 33: 160172, 1990
  • 25
    Russell IJ, Fletcher EM, Michalek JE, McBroom PC, Hester GG: Treatment of primary fibrositis/fibromyalgia syndrome with ibuprofen and alprazolam: a double-blind, placebo-controlled study. Arthritis Rheum 34: 552560, 1991
  • 26
    Mitchell DM, Spitz PW, Young DY, Bloch DA, McShane DJ, Fries JF: Survival, prognosis, and causes of death in rheumatoid arthritis. Arthritis Rheum 29: 706714, 1986
  • 27
    Radloff LS: The CES-scale: a self-report depression scale for research in the general population. Appl Physiol Measurement 1: 385401, 1977
  • 28
    Zung WWK, Durham NC: A self-rating depression scale. Arch Gen Psychiatry 12: 6370, 1965
  • 29
    DeLongis A, Falkman S, Lazarus RS: The impact of daily stress on health and mood. J Pers Soc Psychol 54: 486495, 1988
  • 30
    Dailey PA, Bishop GD, Russell IJ, Fletcher EM: Psychological stress and the fibrositis/fibromyalgia syndrome. J Rheumatol 17: 13801385, 1990
  • 31
    Russell IJ, Vipraio GA, Morgan WW, Bowden CL: Is there a metabolic basis for the fibrositis syndrome? Am J Med 81: 5056, 1986
  • 32
    Fischer AA: Pressure threshold measurement for the diagnosis of myofascial pain and evaluation of treatment results. Clin J Pain 2: 207214, 1987
  • 33
    White KP, McCain GA, Tunks E: Effects of changing the painful stimulus upon dolorimetry scores in patients with fibromyalgia. J Musculoskel Pain 1: 4358, 1993
  • 34
    Vaeroy H, Nyberg F, Franzen H, Terenius L: Characterization of a substance P-GLY12 amidating enzyme in human cerebrospinal fluid. Biochem Biophys Res Commun 148: 2430, 1987
  • 35
    Cohen J: Statistical Power Analysis for the Behavioral Sciences. New York, Academic Press, 1977
  • 36
    Evaskus DS, Laskin DM: A biochemical measure of stress in patients with myofascial pain-dysfunction syndrome. J Dent Res 51: 14641466, 1972
  • 37
    Raskin RJ, Lawless OJ: Articular and soft tissue abnormalities in a “normal” population. J Rheumatol 9: 284288, 1982
  • 38
    Howes RG, Isdale IC: The loose back: an unrecognized syndrome. Rheum Phys Med 11: 7277, 1971
  • 39
    Alderman MM: The management of the patient with myofascial pain dysfunction syndrome (part I). Compendium Continuing Educ Dent 1: 253255, 1980
  • 40
    Wolfe F, Cathey MA: Prevalence of primary and secondary fibrositis. J Rheumatol 10: 965968, 1983
  • 41
    McNeill DL, Westlund KN, Coggeshall RE: Peptide immuno-reactivity of unmyelinated primary afferent axons in rat lumbar dorsal roots. J Histochem Cytochem 37: 10471052, 1989
  • 42
    Hirota N, Kuraishi Y, Hino Y, Sato Y, Satoa M, Takagi H: Met-enkephalin and norphine but not dynorphin inhibit noxious stimuli-induced release of substance P from rabbit dorsal horn in situ. Neuropharmacology 24: 567570, 1975
  • 43
    Kantner RM, Kirby ML, Golstein BD: Increase in substance P in the dorsal horn during a chemogenic nociceptive stimulus. Brain Res 338: 196199, 1975
  • 44
    Kurashi Y, Hirota N, Sugimoto M, Satoh M, Takagi H: Effects of morphine on noxious stimuli-induced release of substance P from rabbit dorsal horn in vivo. Life Sci 33: 693696, 1983
  • 45
    De Koninck Y, Ribeiro-da-Silva A, Henry JL, Cuello AC: Spinal neurons exhibiting a specific nociceptive response receive abundant substance P-containing synaptic contacts. Proc Natl Acad Sci U S A 89: 50735077, 1992
  • 46
    Malmberg A, Yaksh T: Hyperalgesia mediated by spinal glutamate or substance P receptor blocked by spinal cyclooxygenase inhibition. Science 257: 12761279, 1992
  • 47
    Piercey MF, Einspahr FJ, Dobry PJK, Schroeder LA, Hollister RP: Morphine does not antagonize the substance P-mediated excitation of dorsal horn neurons. Brain Res 186: 421434, 1980
  • 48
    Roberts MHT, Wright DM: Functional identification of units in the rat dorsal horn responding to substance P analogue. J Physiol 281: 3334, 1978
  • 49
    Wright DM, Roberts MHT: Response of spinal neurons to a substance P analogue, noxious pinch, and bradykinin. Eur J Pharmacol 64: 165167, 1980
  • 50
    Henry JL: Effects of substance P on functionally identified units in cat spinal cord. Brain Res 114: 439451, 1976
  • 51
    Randic M, Miletic V: Effects of substance P in cat dorsal hore neurons activated by noxious stimuli. Brain Res 128: 164169, 1977
  • 52
    Kellstein DE, Price DD, Hayes RL, Mayer DJ: Evidence that substance P selectively modulates C-fiber-evoked discharges of dorsal horn nociceptive neurons. Brain Res 526: 291298, 1990
  • 53
    Frenk H, Bossut D, Urea G, Mayer DJ: Is substance P a primary afferent neurotransmitter for nociceptive input. I. Analysis of pain-related behaviors resulting from intrathecal administration of substance P and 6 excitatory compounds. Brain Res 455: 223231, 1988
  • 54
    Bossut D, Frenk H, Mayer DJ: Is substance P a primary afferent neurotransmitter for nociceptive input. II. Spinalization does not reduce and intrathecal morphine potentiates behavioral responses to substance P. Brain Res 455: 232239, 1988
  • 55
    Frenk H, Bossut D, Mayer DJ: Is substance P a primary afferent neurotransmitter for nociceptive input. III. Valproic acid and chlordiazepoxide decrease behaviors elicited by intrathecal injection of substance P and excitatory compounds. Brain Res 455: 240246, 1988
  • 56
    Bossut D, Frenk H, Mayer DJ: Is substance P a primary afferent neurotransmitter for nociceptive input. IV. 2-Amino-5-phosphonovalerate (APV) and [D-Pro2, D-Trp7, 9]-substance P exert different effects on behaviors induced by intrathecal substance P, strychnine and kainic acid. Brain Res 455: 247253, 1988
  • 57
    Price DD, Hayes RL, Ruda M, Dubner R: Spatial and temporal transformations of input to spinothalamic tract neurons and their relation to somatic sensations. J Neurophysiol 39: 936953, 1976
  • 58
    Russell IJ: Neurohormonal aspects of fibromyalgia syndrome. Rheum Dis Clin North Am 15: 149168, 1989
  • 59
    Meyerson BJ, Blomqvist A, Ericson AC, Le Greves P: Neonatal exposure to substance P alters behavioral and substance P levels in the central nervous system of the adult rat. Dev Brain Res 59: 163170, 1991
  • 60
    DeFelipe MC, Molinero MT, DelRio J: Long-lasting neurochemical and functional changes in rats induced by neonatal administration of substance P antiserum. Brain Res 485: 301308, 1989
  • 61
    Marabini S, Matucci-Cerinic M, Geppetti P, Del Bianco E, Marchesoni A, Tosi S, Cagnoni M, Partsch G: Substance P and somatostatin levels in rheumatoid arthritis, osteoarthritis, and psoriatic arthritis synovial fluid. Ann N Y Acad Sci 632: 435436, 1991
  • 62
    Marshall KW, Chiu B, Inman RD: Substance P and arthritis: analysis of plasma and synovial fluid levels. Arthritis Rheum 33: 8790, 1990
  • 63
    Almay BG, Johansson F, von Knorring L, Le Greves P, Terenius L: Substance P in CSF of patients with chronic pain syndromes. Pain 33: 39, 1988
  • 64
    Igwe OJ, Sun X, Larson AA: Role of substance P amino terminal metabolites in substance P-induced desensitization in mice. Neuroscience 36: 535542, 1990